ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus.

Total Revenue: $22.7 million in Q1 2026. US Net Product Revenue for Neffy: $17.5 million. Collaboration Revenue: $2.5 million from international partners. Supply Revenue: $2.7 million from international partners. R&D Expenses: $4.3 million. SG&A Expenses: $72.2 million. Gross to Net Range: Low to mid 50% range, targeting approximately 50% at steady state. Cash Equivalents and Short-term Investments: $201 million at the end of Q1 2026.

Warning! GuruFocus has detected 5 Warning Signs with SPRY. Is SPRY fairly valued? Test your thesis with our free DCF calculator.

Release Date: May 15, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

ARS Pharmaceuticals Inc (NASDAQ:SPRY) reported a strong start to 2026 with $22.7 million in total revenue, including $17.5 million in US net product revenue for neffy. The company achieved three times the volume of neffy prescriptions year-over-year and more than doubled the revenue. Approximately 90% of commercial coverage was achieved, with 57% without prior authorization, improving access for patients. The introduction of a $199 retail pharmacy cash option for neffy aims to reduce out-of-pocket costs and improve affordability. Health Canada and the European Commission have approved neffy, expanding its market presence internationally.

Negative Points

The prior authorization process remains a barrier to prescriber adoption, creating friction that can delay or deter prescribing. High retail prices for neffy, sometimes exceeding $1,000, have created confusion and impacted prescribing decisions. SG&A expenses were high at $72.2 million, reflecting significant commercialization investments. The CVS Caremark proposal process has been delayed due to new legislation and ongoing FTC-related interactions. The company is still working to achieve unrestricted Medicaid coverage in the majority of states, which is crucial for market expansion.

Q & A Highlights

Q: Can you talk more about your level of conviction regarding the CVS coverage and the goal of removing prior authorizations by the July 1 effective date? How does this tie in with the back-to-school surge expectation later this summer? A: Eric Karas, Chief Commercial Officer: We are nearing the approval process with CVS Caremark, which represents a significant portion of covered lives. We feel confident based on our conversations and the updated proposal submitted in April. This aligns well with our marketing initiatives and field force efforts targeting top prescribers, which should support the back-to-school surge.

Story Continues

Q: What magnitude of lift might we expect from refills going into later this year, and how should we think about that trend in 2027? A: Richard Lowenthal, President and CEO: We expect renewal prescriptions over the summer as parents prepare for the school year, contributing to peak season sales. This trend should continue into 2027 as the patient base matures and refill cycles become more established.

Q: When do you expect more broadening of prescribing to lower decile accounts, considering your current initiatives? A: Richard Lowenthal, President and CEO: We are already seeing broadening with the expansion of our prescriber base. Typically, physicians trial the product before becoming frequent prescribers. Eric Karas added that over 28,000 physicians have prescribed neffy, and we are seeing traction in both high and lower decile accounts.

Q: How should we think about market share growth into the summer, especially with the expanded sales force? A: Richard Lowenthal, President and CEO: We expect meaningful market share growth, aligning with current consensus even without Caremark. Our streamlined prescribing processes and well-trained sales team should support this growth, particularly as we approach the back-to-school season.

Q: Can you explain the automated conversion process for denied claims and its expected impact on script volumes? A: Richard Lowenthal, President and CEO: The process has been implemented at the pharmacy level to convert denied claims to a $199 cash price, reducing negative feedback to doctors. Eric Karas added that this covers about 90% of pharmacies and should simplify the prescribing process, reducing abandonment rates and improving script volumes.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments